Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be competent to understand the nature of the trial and provide informed consent~* Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the face Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on either the face, the balding scalp (the balding part of the scalp should be at least 25 cm2) or a contiguous area of approximately 250 cm2 on the chest~* Subject at least 18 years of age~* Female subjects must be of either:~  1. Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or,~ 2. Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to trial treatment, to rule out pregnancy~* Female subjects of childbearing potential1 must be willing to use effective contraception at trial entry and until completion~Exclusion Criteria:~* Location of the treatment area (full face, full balding scalp or chest)~  * within 5 cm of an incompletely healed wound,~ * within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC~* Prior treatment with ingenol mebutate gel within the treatment area~* Lesions in the treatment areas that have:~  * atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous horns) and/or,~ * recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions~* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g., eczema, unstable psoriasis, xeroderma pigmentosum)~* Use of cosmetic or therapeutic products and procedures which could interfere with the assessments of the treatment areas.~* Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety and efficacy during the course of the trial, as determined by the investigator's clinical judgment~* Any abnormal laboratory tests that are medically significant and would impact the safety of the subjects or the interpretation of the trial results, as determined by the investigator's judgment~* Anticipated need for hospitalisation or out-patient surgery during the first 15 days after the first trial medication application. Note that cosmetic/therapeutic procedures are not excluded if they fall outside of the criteria detailed in Prohibited Therapies or Medications~* Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel~* Presence of acute sunburn within the treatment areas~* Current enrolment or participation in an investigational clinical trial within 30 days of entry into this trial.~* Subjects previously assigned to treatment in Part 1 or rand~* Female subjects who are breastfeeding.~* In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1A: Ingenol mebutate gel 0.005% (Type: EXPERIMENTAL): Open-label, dose escalation, 3 days treatment
- Part 2: Ingenol mebutate gel 0.018% for 3 days treatment (Type: ACTIVE_COMPARATOR): Randomized, 3 days treatment
- Part 2: Ingenol mebutate gel 0.018% for 2 days treatment (Type: ACTIVE_COMPARATOR): Randomized 2 days treatment
- Part 2: Ingenol mebutate gel 0.027% for 3 days treatment (Type: ACTIVE_COMPARATOR): Randomized 3 days treatment
- Part 2: Ingenol mebutate gel 0.027% for 2 days treatment (Type: ACTIVE_COMPARATOR): Randomized 2 days treatment
- Part 2: Placebo for 3 days treatment (Type: PLACEBO_COMPARATOR): Randomized 3 days treatment
- Part 2: Placebo for 2 days treatment (Type: PLACEBO_COMPARATOR): Randomized 2 days treatment
- Part 1A: Ingenol mebutate gel 0.008% (Type: EXPERIMENTAL): Open-label, dose escalation, 3 days treatment
- Part 1A: Ingenol mebutate gel 0.012% (Type: EXPERIMENTAL): Open-label, dose escalation, 3 days treatment
- Part 1A: Ingenol mebutate gel 0.027% (Type: EXPERIMENTAL): Open-label, dose escalation, 3 days treatment
- Part 1A: Ingenol mebutate gel 0.04% (Type: EXPERIMENTAL): Open-label, dose escalation, 3 days treatment
- Part 1B: Ingenol mebutate gel 0.06% (Type: EXPERIMENTAL): Open-label, dose escalation, 2 days treatment
- Part 1A: Ingenol mebutate gel 0.018% (Type: EXPERIMENTAL): Open-label, dose escalation, 3 days treatment
- Part 1B: Ingenol mebutate gel 0.04% (Type: EXPERIMENTAL): Open-label, dose escalation, 2 days treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete